It is important to note that global loss of Esm1 does not cause a noticeable defect in the brain or other organs, so systematically diminishing or even eliminating tumor-associated Endocan could indeed be a promising strategy to control glioblastoma progression and recurrence. This evidence concerns the gene ESM1 and neoplasm.